Skip to main content
    A

    AstraZeneca PLC (AZN)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE

    $184.45
    +0.07 (+0.04%)

    Market Cap: $286.07B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    AstraZeneca PLC (AZN) Financials: Revenue, Profit and Cash Flow

    Updated Oct 30, 2026. Financial statements from company filings, amounts in US dollars.

    AstraZeneca reported revenue of $58.74B for the fiscal year ended Dec 31, 2025, up 8.6% from the year before. That year, net income was $10.26B with a net margin of 17.5%, operating cash flow was $14.57B and free cash flow was $8.67B. The quarter ended Sep 30, 2026 had revenue of $15.99B and net income of $3.08B.

    Revenue and Margins

    The operating margin was 23.4% in the fiscal year ended Dec 2025, the highest of the 10 years shown. Over the 9 years to Dec 2025, revenue grew from $23.00B, a compound annual rate of 11.0%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$58.74B+8.6%81.9%23.4%17.5%
    Dec 2024$54.07B+18.0%81.1%18.5%13.0%
    Dec 2023$45.81B+3.3%82.0%17.9%13.0%
    Dec 2022$44.35B+18.5%72.1%8.5%7.4%
    Dec 2021$37.42B+40.6%66.8%2.8%0.3%
    Dec 2020$26.62B+9.2%80.1%19.4%12.0%
    Dec 2019$24.38B+10.4%79.8%12.0%5.5%
    Dec 2018$22.09B-1.7%77.7%15.3%9.8%
    Dec 2017$22.46B-2.3%80.8%16.4%13.4%
    Dec 2016$23.00BN/A82.1%21.3%15.2%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, net income rose 45.7% from the year before. In the quarter ended Sep 2026, net income rose 21.7% from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$58.74B$54.07B$45.81B$44.35B$37.42B$26.62B$24.38B$22.09B$22.46B$23.00B
    Cost of revenue$10.63B$10.21B$8.27B$12.39B$12.44B$5.30B$4.92B$4.94B$4.32B$4.13B
    Gross profit$48.11B$43.87B$37.54B$31.96B$24.98B$21.32B$19.46B$17.15B$18.15B$18.88B
    Research and development$14.23B$13.58B$10.94B$9.76B$9.74B$5.99B$6.06B$5.93B$5.76B$5.89B
    Operating income$13.74B$10.00B$8.19B$3.76B$1.06B$5.16B$2.92B$3.39B$3.68B$4.90B
    Net income$10.26B$7.04B$5.96B$3.29B$112.00M$3.20B$1.33B$2.15B$3.00B$3.50B
    EBITDA$19.83B$15.44B$13.42B$9.09B$5.11B$8.08B$6.71B$7.11B$6.62B$7.28B
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024
    Revenue$15.99B$15.38B$15.29B$15.50B$15.19B$14.46B$13.59B$13.59B$14.89B$13.56B$12.94B$12.68B
    Gross profit$11.93B$12.86B$12.61B$12.38B$12.39B$11.98B$11.35B$11.35B$12.17B$10.48B$10.76B$10.46B
    Operating income$4.32B$3.16B$4.25B$2.98B$3.58B$3.51B$3.67B$3.67B$2.04B$2.11B$2.75B$3.12B
    Net income$3.08B$2.51B$3.08B$2.33B$2.53B$2.45B$2.92B$2.92B$1.50B$1.43B$1.93B$2.18B
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, total debt of $28.28B exceeded cash and equivalents by $22.57B.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$114.07B$104.03B$101.12B$96.48B$105.36B$66.73B$61.38B$60.65B$63.35B$62.53B
    Current assets$28.72B$25.83B$25.05B$22.59B$26.24B$19.54B$15.56B$15.59B$13.15B$13.26B
    Cash and equivalents$5.71B$5.49B$5.84B$6.17B$6.33B$7.83B$5.37B$4.83B$3.32B$5.02B
    Total liabilities$65.36B$63.16B$61.95B$59.42B$66.08B$51.09B$46.78B$46.61B$46.71B$45.86B
    Short-term debt$3.57B$2.50B$5.40B$5.45B$1.80B$2.39B$2.01B$1.78B$2.27B$2.33B
    Long-term debt$24.71B$26.51B$22.36B$22.96B$28.13BN/AN/AN/AN/AN/A
    Shareholder equity$48.67B$40.79B$39.14B$37.04B$39.27B$15.62B$13.13B$12.47B$14.96B$14.85B
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024
    Total assets$119.71B$115.70B$114.02B$114.07B$114.46B$112.42B$106.25B$106.25B$104.03B$104.92B$104.34B$102.29B
    Total liabilities$67.99B$65.39B$66.63B$65.36B$68.48B$67.61B$65.12B$65.12B$63.16B$64.12B$64.74B$64.79B
    Cash and equivalents$7.92B$4.89B$7.56B$5.71B$8.14B$7.06B$5.23B$5.23B$5.49B$4.80B$6.92B$7.84B
    Shareholder equity$51.64B$50.24B$47.33B$48.67B$45.89B$44.72B$41.04B$41.04B$40.79B$40.72B$39.51B$37.45B
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Dec 2025, free cash flow was 59.5% of operating cash flow. Dividends came to 57.3% of it.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow$14.57B$11.86B$10.35B$9.81B$5.96B$4.80B$2.97B$2.62B$3.58B$4.14B
    Capital expenditures$5.91B$4.59B$3.78B$2.57B$2.20B$2.61B$2.46B$1.37B$1.62B$2.31B
    Free cash flow$8.67B$7.28B$6.57B$7.24B$3.76B$2.19B$509.00M$1.25B$1.96B$1.83B
    Dividends paid$4.97B$4.63B$4.48B$4.36B$3.86B$3.57B$3.59B$3.48B$3.52B$3.56B
    Investing cash flow-$6.81B-$7.98B-$4.06B-$2.96B-$11.06B-$285.00M-$657.00M$963.00M-$2.33B-$3.97B
    Financing cash flow-$7.54B-$4.00B-$6.57B-$6.82B$3.65B-$2.20B-$1.76B-$2.04B-$2.94B-$1.32B
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024
    Operating cash flow$4.66B$2.89B$3.36B$2.43B$5.13B$3.39B$3.71B$3.71B$2.91B$3.38B$3.08B$2.49B
    Capital expenditures$666.87M$752.85M$1.54B$1.05B$1.73B$1.92B$969.00M$969.00M$955.00M$1.36B$668.00M$1.60B
    Free cash flow$3.99B$2.13B$1.82B$1.38B$3.41B$1.46B$2.74B$2.74B$1.95B$2.02B$2.42B$881.00M
    Last 12 quarters

    Frequently Asked Questions About AZN

    What is AstraZeneca's annual revenue?

    AstraZeneca reported revenue of $58.74B for the fiscal year ended Dec 31, 2025.

    How fast is AstraZeneca's revenue growing?

    Revenue was up 8.6% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 9.8%.

    Is AstraZeneca profitable?

    Yes. AstraZeneca reported net income of $10.26B for the fiscal year ended Dec 31, 2025, with a net margin of 17.5%.

    How much free cash flow does AZN generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of $14.57B minus capital expenditures of $5.91B produced free cash flow of $8.67B.

    How much debt does AstraZeneca have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $24.71B, short-term debt of $3.57B and cash and equivalents of $5.71B.